Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study by Molinari, Chiara et al.
RESEARCH Open Access
Genomic alterations in rectal tumors and
response to neoadjuvant chemoradiotherapy:
an exploratory study
Chiara Molinari
1, Michela Ballardini
2, Nazario Teodorani
3, Massimo Giannini
4, Wainer Zoli
1, Ermanno Emiliani
3,
Enrico Lucci
5, Alessandro Passardi
6, Paola Rosetti
6, Luca Saragoni
7, Massimo Guidoboni
8, Dino Amadori
6 and
Daniele Calistri
1*
Abstract
Background: Neoadjuvant chemoradiotherapy is the treatment of choice in advanced rectal cancer, even though
there are many patients who will not benefit from it. There are still no effective methods for predicting which
patients will respond or not. The present study aimed to define the genomic profile of rectal tumors and to
identify alterations that are predictive of response in order to optimize therapeutic strategies.
Methods: Forty-eight candidates for neoadjuvant chemoradiotherapy were recruited and their pretherapy biopsies
analyzed by array Comparative Genomic Hybridization (aCGH). Pathologic response was evaluated by tumor
regression grade.
Results: Both Hidden Markov Model and Smoothing approaches identified similar alterations, with a prevalence of
DNA gains. Non responsive patients had a different alteration profile from responsive ones, with a higher number
of genome changes mainly located on 2q21, 3q29, 7p22-21, 7q21, 7q36, 8q23-24, 10p14-13, 13q12, 13q31-34,
16p13, 17p13-12 and 18q23 chromosomal regions.
Conclusions: This exploratory study suggests that an in depth characterization of chromosomal alterations by
aCGH would provide useful predictive information on response to neoadjuvant chemoradiotherapy and could help
to optimize therapy in rectal cancer patients.
The data discussed in this study are available on the NCBI Gene Expression Omnibus [GEO: GSE25885].
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Background
The benefits of neoadjuvant chemoradiotherapy (NCRT)
in rectal cancer are well documented. In particular, pre-
operative treatment is indicated to downsize tumors in
order to achieve tumor-free margins, reduce tumor bur-
den and increase the possibility of conservative surgery,
which results in a high rate of sphincter preservation
and significant improvement in local disease control and
survival [1,2]. However, although complete pathologic
response rates of 10-25% can be achieved, more than
one third of patients either do not respond or show
only modest response to treatment [3].
Whilst numerous studies have analyzed the correlation
between expression levels of candidate genes and
response to therapies [4,5], the predictive role of such
genes is controversial and there is still no firm evidence
upon which to base treatment strategies [6]. The gene
expression profile evaluated by cDNA microarray has
recently been found to provide indications about
response of rectal tumors to NCRT [7-9], but such pre-
liminary findings require confirmation in larger patient
cohorts.
It is well known that the altered transcription of genes
frequently depends on genomic copy number changes,
such as deletion of one or both alleles of tumor
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rearrangements [10,11]. Although several basic research
studies have highlighted the presence of non random
patterns of DNA alterations in colorectal cancer [12-15],
almost none of these alterations have been analyzed as
predictive markers of response to clinical treatment,
especially in rectal cancer. It was established only
recently that genomic imbalances detected by metaphase
Comparative Genomic Hybridization (CGH) could be of
value for response prediction [16]. With respect to this
technique, higher resolution mapping of chromosomal
copy number changes can be achieved by array CGH
(aCGH), a technique capably of accurately identifying
even small variations in genomic DNA sequence [17,18].
The main objective of the present study was to define
the molecular profile of rectal cancers in order to iden-
tify markers that are predictive of response to NCRT.
The acquisition of more detailed genomic information
would optimize treatment planning and lead to
improved clinical and cost benefits.
Methods
Patients, samples and treatment
A series of 51 consecutive patients with a confirmed
diagnosis of rectal adenocarcinoma localized in the mid-
low rectum (up to 12 cm from the anal verge) and who
were candidates for NCRT were considered eligible. The
study was approved by the Local Ethics Committee, in
accordance with the ethical standards laid down in the
1964 Declaration of Helsinki. All patients gave their
written informed consent.
After pretherapeutic staging with a computerised
tomography scan and also, in the majority of cases (>
80%), with endorectal ultrasonography, all patients were
treated with a total dose of 50.4 Gy for 5-6 weeks with
conventional fractionation. A daily dose of 225 mg/m
2
of 5-fluorouracil was infused by central catheter during
radiotherapy. Surgery was planned 6-8 weeks after com-
pletion of chemoradiotherapy. The median duration of
the interval between the day after the end of therapy
and surgery was 52.3 ± 10.9 days (range 40-91). Compli-
ance to treatment was good as only 6% (n = 3) of
enrolled patients were excluded because of high toxicity.
Blood samples and tumor biopsies were collected from
patients before therapy. Two biopsies from tumor areas
were taken from each patient; the first was used to
obtain histopathologic confirmation of tumor diagnosis,
while the second was immediately stored at -80°C and,
after microscopic verification of the presence of > 70%
of tumor cells in the former, used for genomic profile
determination. The pathologic response to NCRT was
evaluated using the tumor regression grade (TRG) clas-
sification, according to the criteria proposed by Dworak
[19].
Immunohistochemistry
In parallel, two conventional markers of proliferative
(Ki67) and apoptotic (p21
WAF1) processes were deter-
mined by immunohistochemical (IHC) methods using
the following primary antibodies: anti-Ki67 (clone MM1;
Leica Microsystems, Heidelberg, Germany; working dilu-
tion 1:100) and anti-p21
WAF1 (clone DC-60.2; Neomar-
kers, Fremont, CA, USA; working dilution 1:50). For
antigen retrieval, sections were treated with 10 mM
citrate (pH 6.0) at 98°C for 40 min and were then
immunostained with LSAB+ System-HRP Kit (Dako,
Carpinteria, CA, USA) according to the manufacturer’s
specifications. For Ki67, all washes were performed with
TBS rather than PBS. Both antibodies were visualized by
diaminobenzidine. Two independent observers with no
prior knowledge of clinicopathologic data performed
blinded immunohistochemical analysis. At least 500
cells were evaluated in representative microscopic fields
and results were expressed as a percentage of cell show-
ing nuclear Ki67 or p21
WAF1 staining.
Array comparative genomic hybridization (aCGH)
Whole genome CGH arrays (Cytochip, Bluegnome,
Cambridge, UK), which cover the entire human genome
at a 1-Mb resolution and, in subtelomeric regions, at a
median 250-Kb resolution, were used for the analysis.
Each clone in the array was spotted in quadruplicate.
Genomic DNA was isolated from tumor tissue using
QIAamp DNA MiniKit (Qiagen, Hilden, Germany). A
pool of normal female or male genomic DNA from
healthy individuals was used as a reference, depending
on patient gender. Approximately 1.2 μgo fD N Aw a s
labelled by random priming (BioPrime Labeling System,
Invitrogen, Milan, Italy), using 1.4 μl of 1 mmol/L Cy3-
dCTP or Cy5-dCTP (Perkin-Elmer Life Sciences, Wal-
tham, MA, USA) according to the manufacturer’s
instructions. Equal amounts of labelled tumor and refer-
ence DNA were mixed and unincorporated fluoro-
chromes were removed using Bioprime Array-CGH
Purification Module (Invitrogen). DNA was then preci-
pitated with 140 μl of blocking mix (TechnoGenetics-
Bouty, Milan, Italy), 6 μl of yeast tRNA 10 mg/ml
(Sigma-Aldrich, St. Louis, MO, USA), 0.1 V/V of 3 M
sodium acetate pH 5.2 and 2 V/V of absolute ethanol.
The DNA pellet was dissolved in 10 μl of distilled water
and 30 μl of hybridization solution (TechnoGenetics-
Bouty). After denaturation at 72°C for 10 min and incu-
bation at 37°C for 30 min, the solution was applied to
the array. Hybridization was done in a Hyb Chamber
(Biorad, Hercules, CA, USA), which was then incubated
at 42°C for 40 h. Finally, the slides were washed accord-
ing to the supplier’s instructions, dried by spinning in a
centrifuge for 5 min at 1000 rpm and scanned on a Ver-
saArray ChipReader scanner (Biorad).
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Images were analyzed using BlueFuse version 3.5 soft-
ware (BlueGnome), permitting an automated approach to
aCGH. Spots were excluded when the quality flag was <
1, the confidence value < 0.3 or the standard deviation of
quadruplicate > 0.2. Log2 ratios of spots that were not
excluded were normalized using block median or block
lowess approaches. Alteration analysis was performed
using two different approaches: (1) aCGH-Smooth
approach [20], implemented in BlueFuse version 3.5 soft-
ware; (2) Hidden Markov Model (HMM) approach,
implemented in the aCGH package [21-23]. Molecular
analyses were performed in a blinded manner.
Statistics
Statistical analyses were carried out using SPSS (SPSS
Inc, Chicago, IL, USA) and SAS (release 9.1, SAS Insti-
tute, Cary, NC, USA) statistical software. The Kruskal-
Wallis non parametric test was used to assess the pre-
dictive relevance of genomic instability, expressed as the
fraction of genome altered (FGA) in relation to response
to therapy in different stage and age subgroups. The
Pearson chi-square test and Fisher’s exact test were used
to analyze the relation between patient characteristics
and response to NCRT, defined according to TRG cri-
teria, and the difference in the frequency of altered
regions among response groups, respectively.
Results
Clinical parameters and pathologic response to NCRT
Information on patient and tumor characteristics and on
response to NCRT is shown in Table 1. On the basis of
TRG criteria proposed by Dworak, 13 (27%) patients
reached TRG4, ie, complete tumor regression; 8 (17%),
17 (35%) and 9 (19%) reached TRG3, TRG2, and TRG1,
respectively. Only 1 (2%) case was classified as TRG0, ie,
did not show any pathologic response. To further sim-
plify the analysis and summarize clinically relevant
results, patients were grouped into two subsets, as
already done by other authors [7]: those who achieved
TRG0-2 (56%) were defined as non responders, while
patients who obtained TRG3-4 (44%) were considered
responders. Analysis of the relationship between clinical
pretreatment parameters and pathologic response did not
reveal any significant association. However, a significant
correlation (p = 0.0004) was found between TRG and
ypT, with 57% of responsive patients who were ypT0 and
52% of non responsive patients who were ypT3. Conver-
sely, no association was found between ypN and TRG.
Ki67 and p21
WAF1 expression and pathologic response to
NCRT
Ki67 and p21
WAF1 expression was determined in 35/48
(73%) and 34/48 (71%) of cases, respectively, due to
insufficient bioptic material. Median Ki67 index was
69% in the overall series (range 23-93) and was similar
in responsive (69%; range 23-85) and non-responsive
(69.5%; range 29-93) patients. With regard to p21
WAF1,
the median value of positive cells was 4% (range 0-46),
specifically 5.5% (range 0-17) in the responsive group
and 2.5% (range 0-46) in the non responsive group. No
correlations were observed between pathologic response
and Ki67 or p21
WAF1 expression.
Genomic profile and pathologic response to NCRT
Validation of aCGH approach
The performance and reproducibility of our aCGH
approach was validated by dye swap and normal/normal
experiments (data not shown). Specifically, we per-
formed three array CGH analyses of normal female
(XX) DNA against normal male (XY) DNA extracted
from blood samples. No copy number changes were
Table 1 Patient and tumor characteristics
No. of
patients
(%)
Gender
Male 36 (75)
Female 12 (25)
Age (y)
Median 66
Range 37-82
uT stage
2 7 (15)
3 39 (81)
4 2 (4)
uN stage
0 27 (56)
+ 21 (44)
ypT stage*
0 14 (30)
1 6 (13)
2 11 (23)
3 16 (34)
ypN stage*
0 37 (78)
+ 10 (22)
TRG
§
0 1 (2)
1 9 (19)
2 17 (35)
3 8 (17)
4 13 (27)
TRG response
Responsive 21 (44)
Non Responsive 27 (56)
*Data was not available for one patient
§ According to Dworak [19]
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the log2 values of the average normalized fluorescence
ratios for all the autosomal loci showed two copies,
whereas the fluorescence ratios for the chromosomes X
and Y loci indicated the gain and loss of one DNA copy,
respectively. These experiments also permitted us to
establish the best thresholds for significant DNA altera-
tions (loss: log2 ratios < - 0.3219; gain: log2 ratios >
0.2630).
HMM analysis and unsupervised hierarchical clustering
The FGA identified by HMM analysis was 4.19% ± 7%
(range 1.7-29%), with FGA-gain of 2.4% ± 4.4% (range
0.47-18.1%) and FGA-loss of 1.8% ± 3.2% (range 0.2
-15.6%). No significant associations were observed
between FGA and pathologic response, other clinical
parameters, or Ki67/p21
WAF1 expression.
The loss of genomic copies was more frequent on
chromosome arms 1p, 8p, 17p, 18p and 18q, and 22q,
while chromosome regions on 7p and 7q, 8q,13q, and
20p and 20q were frequently amplified (Figure 1). Small
regions of relevant copy number changes (log2 ratio >
0.9 for high-level gain and log2 ratio < -0.75 for high-
magnitude deletions) were also observed. High-level
gain was observed in 10 tumors, 9 of which were non
responsive according to TRG classification, and
occurred most frequently in chromosome 7 (4/10), 13
(4/10), 17 (3/10) and 20 (5/10).
Unsupervised hierarchical clustering of the 48 tumors
showed molecular heterogeneity and 5 well-defined clus-
ters (1-5) were identified (Figure 2). The noteworthy
peculiarity among the clusters was the difference in
response to NCRT. The three main clusters (1, 2 and 4)
included 83% of cases. In cluster 1 (21% of cases), 70%
of patients were responders on the basis of TRG, while
in clusters 2 (33%) and 4 (29%), 43% and 29% of
patients responded to NCRT, respectively (p< 0.0001). If
only patients with extreme differences in response to
NCRT (TRG4 versus TRG0-1) were considered, for
clusters 1, 2 and 4 the total number of patients that
reached TRG4 were 40%, 25% and 21%, respectively (p
= 0.0005). We also performed supervised clustering but
did not identify any specific signature, possibly because
of the small number of cases (data not shown).
Smoothing analysis
Smoothing analysis of all DNA copy number changes
showed that the FGA was 1.33% ± 4% (range 0-14.6%).
The most frequent alteration was the gain of genomic
regions. In our tumor series, a total of 3888 clones were
gained (FGA-gain 1.17% ± 3.7%; range 0-14.6%) and 517
were lost (FGA-loss 0.16% ± 0.8%; range 0-3%). Some
alterations involved entire or extensive portions of chro-
mosome arms and mainly affected the long arm of chro-
mosomes 13 and 20, with a 31% and 38% gain
Figure 1 Frequencies of all significant gains and losses in 48
rectal cancers, obtained with HMM analysis. Red bars show copy
number gains and green bars, copy number losses. The boundaries
of individual chromosomes and the location of centromers are
indicated by vertical bars.
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Figure 2 Unsupervised hierarchical clustering of 48 rectal
cancers analyzed by HMM. Clones are shown in chromosomal
order from 1ptel to 22qtel (red, gain; green, loss; yellow spots, high
level gain). Tumor regression grade (TRG) classification: responders
(TRG3-4) yellow; non responders (TRG0-2) black. Extreme response
classes are reported in the upper line: TRG4 yellow and TRG0-1
black. ypT status: ypT0-1green; ypT2 orange and ypT3 red. ypN
status: ypN0 green, ypN1 red and ypNx white.
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detected on specific genomic regions, e.g.o n7 p 2 2 - 2 1
and 8q12, which were amplified in about 13% and 16%
of patients, respectively. An average of 80 clones showed
high-level alterations, mainly gain, with a high percen-
tage (49%) located on chromosome 20q.
The analysis of the relationship between FGA and
response to NCRT according to TRG did not reach sta-
tistical significance. However, the evaluation of tumor
aCGH profiles clearly showed differences between the
two response groups with regard to type and/or fre-
quency of DNA alterations at specific chromosomal
regions (2q21, 3q29, 7p22-21, 7q21, 7q36, 8q23-24,
10p14-13, 13q12, 13q31-34, 16p13, 17p13-12, 18q23)
(Table 2). Among the most altered clones were those
mapping in 2q21.1, which were amplified in non respon-
sive patients and deleted in responsive ones. A number
of clones were altered in only responsive or non respon-
sive patients, such as clones in 7q21.11, amplified in
10% of responsive patients, or clones in 7q36.1-3 or
16p13.3 regions, amplified in 15% and 11% of non
responsive patients, respectively. Finally, high-level
alterations were distributed differently with respect to
response to NCRT, with 85% of patients who showed
this kind of alteration in the group of non responsive
cases.
Genomic profile and pathologic TNM after NCRT
Information on pathologic stage and lymph node status
after NCRT (ypT and ypN) was available for 47/48
patients. Among these, 30% had ypT0 while 13%, 23%
and 34% had ypT1, ypT2, ypT3 respectively. With
regard to ypN, 78% of patients were ypN0, whereas 22%
had a lymph node involvement at the time of surgery.
FGA was significantly different in tumors that showed
different pathologic stages after NCRT, with a higher
frequency of alterations in tumors that had an advanced
Ts t a g e( p < 0.05). With respect to ypT stage, the five
groups identified by hierarchical clustering showed a dif-
ferent frequency of ypT0-1, ypT2 and ypT3 tumors. In
particular, grouping together clusters 1 and 2 (left side
of Figure 2), and clusters 3, 4 and 5 (right side of Figure
2), the percentage of different ypT-stage tumors was as
follows: 56% and 27% of ypT0-1, 16% and 32% of ypT2,
and 28% and 41% of ypT3, respectively. This difference
was statistically significant (p< 0.0001). No association
was observed between FGA and ypN, and no differences
were noted between clusters with regard to ypN status.
Discussion
Neoadjuvant chemoradiotherapy followed by surgery is
accepted as the therapy of choice in rectal cancer. How-
ever, although good results have been obtained with
current treatment strategies, clinically identical tumors
sometimes differ in their response, and more persona-
lized treatments would undoubtedly yield greater bene-
fits [24].
The two most widely adopted systems of assessing
response are tumor regression grade (TRG), according
to Mandard or Dworak criteria, and downstaging. How-
ever, there is still no general consensus as to which one
is the most accurate and the most clinically relevant for
patient prognosis [7,25-28]. In our study, we adopted
the TRG system proposed by Dworak [19] (the response
classification system used by our pathologists), grouping
TRG 0-2 tumors as non responders and TRG 3-4
tumors as responders. This type of division has also
been proposed by numerous other authors [19,7,25] and
Table 2 Number and frequency of principal aberrations distinguishing patients belonging to extreme response classes
Chromosomal band TRG0-1 TRG4 p value
Amplifications Deletions Amplifications Deletions
%%%%
2q21 10 0 0 15 < 0.0001
3q29 20 0 0 0 < 0.0001
7p22-21 20 0 8 0 0.0237
7q21 0 0 15 0 < 0.0001
7q36 20 0 8 0 0.0237
8q23-24 30 0 15 0 0.0171
10p14-13 20 0 0 0 < 0.0001
13q12 30 0 15 0 0.0171
13q31-32 30 0 15 0 0.0171
13q34 40 0 15 0 < 0.0001
16p13 20 0 0 0 < 0.0001
17p13-12 0 20 0 8 0.0237
18q23 10 20 0 0 < 0.0001
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[25].
We did not find any significant correlation between
pathologic response to NCRT and clinical pretreatment
parameters. In addition, the small number of patients
evaluated prevents us from drawing any definitive con-
clusions about the correlation between Ki67 and
p21
WAF1 expression (markers involved in cell cycle con-
trol and proliferation) and TRG. We did, however,
observe a higher median value of p21
WAF1 protein
expression in responsive tumors.
Although several studies have investigated colorectal
cancer by the aCGH approach to better characterize the
alterations of this tumor [29-31], few have focused on
rectal cancer [32]. Furthermore, to our knowledge, the
only study analyzing rectal cancer genomic imbalances in
relation to response used metaphase CGH and concluded
that the probability of detecting copy number changes by
chance was high [16]. In our case series, analysis of
tumor DNA using higher resolution scanning with aCGH
showed that the fraction of altered genome obtained
using the HMM approach (4.19%) was slightly higher
than that obtained by Smoothing analysis (1.33%); this is
to be expected as the latter considers only larger altera-
tions. However, both approaches appear to identify simi-
lar alterations, with a prevalence of DNA gains.
According to the literature [12-14,16,29-32], the most
frequent DNA alterations specific for this tumor were
gains of chromosome arms 7p and 7q, 8q, 13q, 20p and
20q, and losses in 1p, 8p, 17p, 18p and 18q and 22q. In
our case-series, 38% of tumors showed a gain at 20q
chromosome arm, where multiple candidate oncogenes
associated with increased proliferative activity, reduced
survival and progression of colorectal cancer (e.g.
ZNF217, CYP24 and AURKA), are mapped [12,33].
With regard to differences in genomic alterations
between responsive and non responsive tumors, whether
revealed by HMM or Smoothing analyses, our results
showed that a higher number of genome changes was
associated, albeit not significantly, with resistance to
treatment, in contrast to findings published by Grade
and colleagues [16].
The overall difference in genomic instability between
responders and non responders could be due to the fact
that gene drivers of genetic alterations, i.e.g e n e s
involved in DNA repair, mitotic checkpoints and carci-
nogen detoxification, are frequently also involved in the
response to therapies which act by targeting proliferat-
ing cells and damaging DNA. In our case series, how-
ever, the association between FGA and pathologic
response was not significant, probably owing to the
small number of patients enrolled and to the complex
pathways involved in genomic stability which may them-
selves influence response to therapy.
Our clustering analysis indicates a difference in
response to NCRT among patients with a specific
DNA alteration pattern. In particular, in cluster 1 we
observed 70% of responders, whereas in cluster 4 more
than 70% of patients were non responders. Even con-
sidering only the extreme response classes (TRG4 as
responders versus TRG0-1 as non responders), there is
a similar distribution of TRG4 in clusters 1, 2 and 4.
Moreover, in view of the important role played by final
pathologic stage in determining prognosis, we also
took into account the relationships between ypTNM,
response to therapy and genomic alterations. A signifi-
cant correlation was found between TRG and ypT, as
well as a significant association between HMM-
detected FGA and ypT stage. In fact, a higher number
of DNA alterations in pretreatment tumors was asso-
ciated with higher pathologic tumor stage obtained
after NCRT. In the hierarchical clustering was con-
firmed a statistically different frequency of ypT: in par-
ticular, in clusters 1 and 2 (46% of non responders),
the vast majority of cases were ypT0-T1, whereas in
clusters 3-5 (68% of non responders), ypT3 tumors
were predominant (p< 0.0001).
In our case series, specific chromosomal regions pre-
senting alterations capable of distinguishing between
responsive and non responsive tumors, e.g. 2q21, 3q29,
7p22-21, 7q21, 7q36, 8q23-24, 10p14-13, 13q12, 13q31-
34, 16p13, 17p13-12 and 18q23 were observed. Several
alterations, such as that in the 7q36.1-7q36.3 region
(sometimes amplified in non responsive patients),
appear interesting as a number of important genes map
there; these genes are mainly involved in transcription,
cell-cell signalling, chromosome stability and DNA
repair, cell growth, differentiation and oncogenic trans-
formation, e.g. MLL3 and XRCC2, known to be altered
in colorectal cancer [34,35]. We also observed fairly
marked differences in chromosome 13 alterations
between tumors from patients who benefited from
NCRT and those from patients who did not. In fact,
both HMM and Smoothing approaches identified a gain
of several clones spanning the 13q31-34 region in
numerous patients, the vast majority of whom were not
responsive to treatment.
The preferential gain of 13q regions in non responders
is of particular interest because of the relevance of a
number of genes located within these regions, e.g.
Wave3, which contributes to tumor cell invasion and
metastasis [36]; XPO4, an exportin that plays a primary
role in the nucleocytoplasmic shuttling of Smad3 [37];
and APC6/CDC16, a subunit of the anaphase-promoting
complex in which amplification and overexpression may
lead to chromosomal instability [38].
Furthermore, genes that play a role in the control of
cell division and growth regulation, migration and
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these chromosomal bands [39,40]. Two other interesting
genes, CLDN10 and ABCC4, localized in 13q31-34, may
be involved in determining resistance to therapy. The
former encodes a member of the claudin family, integral
membrane proteins and components of tight junction
strands associated with cell invasion and migration [41].
The latter gene, ABCC4/MRP4, belongs to the ABC-
type multidrug transporter family that mediates drug
resistance by energy-dependent drug efflux from cells
and seems to be implicated in resistance to purine ana-
logs and to other nucleoside-based antiviral drugs
[42,43].
Another interesting region, deleted in some non
responsive patients of our case series, is localized at
17p12.1. LLGL1, a candidate tumor suppressor gene
involved in the maintenance of epithelial integrity
through its cytoskeletal interactions, maps in this chro-
mosomal band. As highlighted in some studies, LLGL1
is deleted preferentially in CIN-type tumors [30], and
the downregulation of this gene would seem to contri-
bute to colorectal cancer progression [44].
It is known that there is often a correlation between
genomic copy number and gene expression levels as
DNA imbalances seem to have a direct effect on the
deregulation of the transcriptional profile of cancer cells
[45]. Gene expression signature studies in rectal cancer
patients subjected to neoadjuvant therapy have shown
that different approaches yield different gene sets which
may be predictive of response. Genes involved in com-
mon molecular pathways and cellular processes have
been identified, including those involved in DNA damage
repair, microtubule organization, apoptosis, transcription,
cell growth, signal transduction, drug metabolism, and
transport functions [7-9,46]. Our results are in line with
such findings as the main differences in DNA copy num-
ber between responsive and non responsive patients were
observed in genes involved in DNA damage response,
transcription, cell cycle and mitosis regulation, excretion,
intercellular junction assembly and calcium-independent
cell-cell adhesion pathways.
Conclusions
T h er e s u l t sf r o mt h ep r e s e n ts t u d yi n d i c a t et h a tt h e
aCGH technique could be a potentially useful tool to
better characterize rectal cancer. Our findings also sug-
gest that genome-wide profiling could be used to distin-
guish between patients who respond to NCRT and
those who do not, although further genomic studies in
larger patient cohorts are needed to better classify the
differences in DNA copy number changes between
responsive and non responsive patients. Research is
ongoing to confirm these preliminary data.
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